Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014, Article ID 540326, 14 pages
http://dx.doi.org/10.1155/2014/540326
Research Article

Effects of Fenofibrate on Adiponectin Expression in Retinas of Streptozotocin-Induced Diabetic Rats

1Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei 100, Taiwan
2Department of Ophthalmology, National Taiwan University Hospital, Taipei 100, Taiwan
3Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan
4Department of Ophthalmology, National Taiwan University Hospital, College of Medicine, National Taiwan University, No. 7 Chung-Shan South Road, Taipei 100, Taiwan

Received 23 August 2014; Revised 10 November 2014; Accepted 10 November 2014; Published 1 December 2014

Academic Editor: Subrata Chakrabarti

Copyright © 2014 Ying-Jung Hsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Sharma, A. Oliver-Fernandez, W. Liu, P. Buchholz, and J. Walt, “The impact of diabetic retinopathy on health-related quality of life,” Current Opinion in Ophthalmology, vol. 16, no. 3, pp. 155–159, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. D. S. Fong, L. P. Aiello, F. L. Ferris III, and R. Klein, “Diabetic retinopathy,” Diabetes Care, vol. 27, no. 10, pp. 2540–2553, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Zorena, “Anti-inflammatory therapy in diabetic retinopathy,” Mediators of Inflammation, vol. 2014, Article ID 947896, 2 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Doganay, C. Evereklioglu, H. Er et al., “Comparison of serum NO, TNF-α, IL-1β, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus,” Eye, vol. 16, no. 2, pp. 163–170, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Hernández, R. M. Segura, A. Fonollosa, E. Carrasco, G. Francisco, and R. Simó, “Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy,” Diabetic Medicine, vol. 22, no. 6, pp. 719–722, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. W. Zhang, H. Liu, M. Al-Shabrawey, R. Caldwell, and R. Caldwell, “Inflammation and diabetic retinal microvascular complications,” Journal of Cardiovascular Disease Research, vol. 2, no. 2, pp. 96–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Yamauchi, J. Kamon, H. Waki et al., “The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity,” Nature Medicine, vol. 7, no. 8, pp. 941–946, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. W.-S. Yang, W.-J. Lee, T. Funahashi et al., “Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 8, pp. 3815–3819, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Yamauchi, M. Iwabu, M. Okada-Iwabu, and T. Kadowaki, “Adiponectin receptors: a review of their structure, function and how they work,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 28, no. 1, pp. 15–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Hadjadj, R. Aubert, F. Fumeron et al., “Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects,” Diabetologia, vol. 48, no. 6, pp. 1088–1092, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Ouchi, H. Kobayashi, S. Kihara et al., “Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells,” Journal of Biological Chemistry, vol. 279, no. 2, pp. 1304–1309, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Shibata, N. Ouchi, S. Kihara, K. Sato, T. Funahashi, and K. Walsh, “Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of AMP-activated protein kinase signaling,” The Journal of Biological Chemistry, vol. 279, no. 27, pp. 28670–28674, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Kato, H. Osawa, M. Ochi et al., “Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy,” Clinical Endocrinology, vol. 68, no. 3, pp. 442–449, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Zietz, C. Buechler, K. Kobouch, M. Neumeier, J. Schölmerich, and A. Scäffler, “Serum levels of adiponectin are associated with diabetic retinopathy and with adiponectin gene mutations in Caucasian patients with diabetes mellitus type 2,” Experimental and Clinical Endocrinology and Diabetes, vol. 116, no. 9, pp. 532–536, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Mao, H. Peng, Q. Li et al., “Aqueous humor and plasma adiponectin levels in proliferative diabetic retinopathy patients,” Current Eye Research, vol. 37, no. 9, pp. 803–808, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Costagliola, A. Daniele, R. dell'Omo et al., “Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection,” Experimental Eye Research, vol. 110, pp. 50–54, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Lin, Y. Qiu, Y. Liu, R. Mohan, Q. Li, and B. Lei, “Expression of adiponectin and its receptors in type 1 diabetes mellitus in human and mouse retinas,” Molecular Vision, vol. 19, pp. 1769–1778, 2013. View at Google Scholar · View at Scopus
  18. R. S. Rosenson, “Fenofibrate: treatment of hyperlipidemia and beyond,” Expert Review of Cardiovascular Therapy, vol. 6, no. 10, pp. 1319–1330, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Keech, P. Mitchell, P. Summanen et al., “Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial,” The Lancet, vol. 370, no. 9600, pp. 1687–1697, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Y. Chew, W. T. Ambrosius, M. D. Davis et al., “Effects of medical therapies on retinopathy progression in type 2 diabetes,” The New England Journal of Medicine, vol. 363, no. 3, pp. 233–244, 2010. View at Publisher · View at Google Scholar
  21. M. Villarroel, M. Garcia-Ramírez, L. Corraliza, C. Hernández, and R. Simó, “Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation,” Diabetologia, vol. 54, no. 6, pp. 1543–1553, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. W. L. Chen, Y. L. Chen, Y. M. Chiang, S. G. Wang, and H. M. Lee, “Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARα/AMPK/FoxO1/ATGL pathway,” Biochemical Pharmacology, vol. 84, no. 4, pp. 522–531, 2012. View at Publisher · View at Google Scholar
  23. K. Oki, J. Koide, S. Nakanishi, R. Nakashima, and K. Yamane, “Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia,” Endocrine Journal, vol. 54, no. 3, pp. 431–435, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. K. K. Koh, M. J. Quon, S. Lim et al., “Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia,” Atherosclerosis, vol. 214, no. 1, pp. 144–147, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Neumeier, J. Weigert, A. Schäffler et al., “Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors,” Biochemical and Biophysical Research Communications, vol. 334, no. 3, pp. 924–929, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. S. M. Rahman, I. Qadri, R. C. Janssen, and J. E. Friedman, “Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis,” The Journal of Lipid Research, vol. 50, no. 11, pp. 2193–2202, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Castillero, A. I. Martin, M. P. Nieto-Bona et al., “Fenofibrate administration to arthritic rats increases adiponectin and leptin and prevents oxidative muscle wasting,” Endocrine Connections, vol. 1, no. 1, pp. 1–12, 2012. View at Publisher · View at Google Scholar
  28. M. Gao, L. Bu, Y. Ma, and D. Liu, “Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice,” PLoS ONE, vol. 8, no. 6, Article ID e65641, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Okamoto, S. Kihara, N. Ouchi et al., “Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice,” Circulation, vol. 106, no. 22, pp. 2767–2770, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. V. C. Besson, X. R. Chen, M. Plotkine, and C. Marchand-Verrecchia, “Fenofibrate, a peroxisome proliferator-activated receptor α agonist, exerts neuroprotective effects in traumatic brain injury,” Neuroscience Letters, vol. 388, no. 1, pp. 7–12, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Fujii, A. Okada, T. Yasui et al., “Effect of adiponectin on kidney crystal formation in metabolic syndrome model mice via inhibition of inflammation and apoptosis,” PLoS ONE, vol. 8, no. 4, Article ID e61343, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Wu, B. Xu, W. Fan, X. Zhu, G. Wang, and A. Zhang, “Adiponectin protects Leydig cells against proinflammatory cytokines by suppressing the nuclear factor-κB signaling pathway,” FEBS Journal, vol. 280, no. 16, pp. 3920–3927, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Mahadev, X. Wu, S. Donnelly, R. Ouedraogo, A. D. Eckhart, and B. J. Goldstein, “Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells,” Cardiovascular Research, vol. 78, no. 2, pp. 376–384, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. W. Zhu, K. K. Y. Cheng, P. M. Vanhoutte, K. S. L. Lam, and A. Xu, “Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention,” Clinical Science, vol. 114, no. 5-6, pp. 361–374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Y. L. Li, K. K. Y. Cheng, K. S. L. Lam, P. M. Vanhoutte, and A. Xu, “Cross-talk between adipose tissue and vasculature: role of adiponectin,” Acta Physiologica, vol. 203, no. 1, pp. 167–180, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Tan, F. Wang, M. Zhang, D. Guo, Q. Zhang, and S. He, “High adiponectin and adiponectin receptor 1 expression in synovial fluids and synovial tissues of patients with rheumatoid arthritis,” Seminars in Arthritis and Rheumatism, vol. 38, no. 6, pp. 420–427, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Kusunoki, K. Kitahara, F. Kojima et al., “Adiponectin stimulates prostaglandin E2 production in rheumatoid arthritis synovial fibroblasts,” Arthritis and Rheumatism, vol. 62, no. 6, pp. 1641–1649, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Abke, M. Neumeier, J. Weigert et al., “Adiponectin-induced secretion of interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1, CCL2) and interleukin-8 (IL-8, CXCL8) is impaired in monocytes from pateints with type I diabetes,” Cardiovascular Diabetology, vol. 5, article 17, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. B. H. Rovin and H. Song, “Chemokine induction by the adipocyte-derived cytokine adiponectin,” Clinical Immunology, vol. 120, no. 1, pp. 99–105, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. J.-C. Fruchart, “Peroxisome proliferator-activated receptor-alpha (PPARα): at the crossroads of obesity, diabetes and cardiovascular disease,” Atherosclerosis, vol. 205, no. 1, pp. 1–8, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Grabacka and K. Reiss, “Anticancer properties of PPARα—effects on cellular metabolism and inflammation,” PPAR Research, vol. 2008, Article ID 930705, 9 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Ogata, T. Miyauchi, S. Sakai, M. Takanashi, Y. Irukayama-Tomobe, and I. Yamaguchi, “Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway,” Journal of the American College of Cardiology, vol. 43, no. 8, pp. 1481–1488, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Weyer, T. Funahashi, S. Tanaka et al., “Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 5, pp. 1930–1935, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. J. L. Wilkinson-Berka and A. G. Miller, “Update on the treatment of diabetic retinopathy,” The Scientific World Journal, vol. 8, pp. 98–120, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. N. Komura, N. Maeda, T. Mori et al., “Adiponectin protein exists in aortic endothelial cells,” PLoS ONE, vol. 8, no. 8, Article ID e71271, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Perri, D. Vizza, D. Lofaro et al., “Adiponectin is expressed and secreted by renal tubular epithelial cells,” Journal of Nephrology, vol. 26, no. 6, pp. 1049–1054, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Barb, C. J. Williams, A. K. Neuwirth, and C. S. Mantzoros, “Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence,” The American Journal of Clinical Nutrition, vol. 86, no. 3, pp. s858–s866, 2007. View at Google Scholar · View at Scopus
  48. G. Chinetti, C. Zawadski, J. C. Fruchart, and B. Staels, “Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXR,” Biochemical and Biophysical Research Communications, vol. 314, no. 1, pp. 151–158, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Yoneda, A. Tomimoto, H. Endo et al., “Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue,” Oncology Reports, vol. 20, no. 3, pp. 479–483, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Tan, X.-Q. Ding, A. Saadi, N. Agarwal, M. I. Naash, and M. R. Al-Ubaidi, “Expression of cone-photoreceptor-specific antigens in a cell line derived from retinal tumors in transgenic mice,” Investigative Ophthalmology & Visual Science, vol. 45, no. 3, pp. 764–768, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Hayakawa, A. Hayashi, M. Miyakawa et al., “Studies on the risk factors for fenofibrate-induced elevation of liver function tests,” Yakugaku Zasshi, vol. 122, no. 2, pp. 169–175, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Y. Ho, T. H. Kuo, T. S. Chen et al., “Fenofibrate-induced acute cholestatic hepatitis,” Journal of the Chinese Medical Association, vol. 67, no. 5, pp. 245–247, 2004. View at Google Scholar
  53. K. Dohmen, C.-Y. Wen, S. Nagaoka et al., “Fenofibrate-induced liver injury,” World Journal of Gastroenterology, vol. 11, no. 48, pp. 7702–7703, 2005. View at Google Scholar · View at Scopus
  54. M. K. Arora, K. Reddy, and P. Balakumar, “The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy,” European Journal of Pharmacology, vol. 636, no. 1–3, pp. 137–144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Baraka and H. AbdelGawad, “Targeting apoptosis in the heart of streptozotocin-induced diabetic rats,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 15, no. 2, pp. 175–181, 2010. View at Google Scholar